dupilumabi
Dupilumab, sometimes spelled dupilumabi, is a human monoclonal antibody used to treat several inflammatory diseases driven by type 2 (Th2) immune responses. It targets the interleukin-4 receptor alpha subunit (IL-4Rα), blocking signaling of both IL-4 and IL-13. By inhibiting these pathways, dupilumab reduces eosinophilic inflammation and itch in the skin and airways.
Dupilumab was developed by Sanofi and Regeneron and is marketed under the brand name Dupixent. It has
Administration is by subcutaneous injection, typically given every two weeks after an initial loading regimen. Dosing
Clinical use and outcomes vary by condition. In atopic dermatitis, dupilumab has shown improvements in skin
Safety considerations include common adverse events like injection-site reactions, conjunctivitis, and keratitis. There is also a